For patients with mHSPC
In a clinical study evaluating overall survival, 651 patients taking NUBEQA + hormone therapy* + docetaxel (chemotherapy) were compared to 654 patients taking hormone therapy + docetaxel alone

32% lower risk of death

Median for the treatment groups were: NR (not reached) for NUBEQA + docetaxel (NR, NR) and 48.9 (44.4, NR) for placebo + docetaxel.

*Hormone therapy includes drug treatments to lower testosterone or surgery.

Median is the middle value in a set of numbers, not the average.

For patients with nmCRPC
In a clinical study evaluating metastasis-free survival (MFS), 955 patients taking NUBEQA + hormone therapy were compared to 554 patients taking hormone therapy alone§

men lived 2x longer without cancer spreading (median 3.4 yrs vs 1.5 yrs)

In the same study, looking at overall survival (OS) men had a 31% lower risk of death

§The clinical study in nmCRPC was designed to measure metastasis-free survival (MFS) and also overall survival. 

How do you pronounce NUBEQA?

(new-BECCA)

Press to hear pronunciation

Icon of 3 people on hand showing caregiver support

Caregivers: Thanks for Being Here

You have access to helpful tips and resources created just for you.

Question mark icon

Frequently Asked Questions

It's natural to have questions, so we have the answers all in one place.

Download icon

NUBEQA Patient Brochure

Find out more about NUBEQA and what it means for your type of prostate cancer.

Patient Stories

You are not alone. See the stories of men taking NUBEQA and what their caregivers have to say.

Dr. Tom Green’s Story

Learn more about Dr. Green, a urologist and NUBEQA patient himself, as he talks about navigating diagnosis and treatment.

Dick and Jan’s Story

See how NUBEQA patient Dick navigates life after diagnosis as he continues to pursue his passions with the support of his loving wife, Jan.